Compare Boston Scientific Corporation (BSX) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Open Text Corporation — how do they compare? Boston Scientific Corporation trades at $51.57 (market cap $74.19B), while Open Text Corporation trades at $23.64 (market cap $5.80B). The key difference: Boston Scientific Corporation is far larger — about 12.8× Open Text Corporation's market cap, and Open Text Corporation pays a 4.67% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | OTEX | |
|---|---|---|
Market Cap | $74.19B | $5.80B |
Sector | Health | Technology |
52-Week High | $108.14 | $39.69 |
52-Week Low | $42.63 | $20.01 |
Enterprise Value | $86.27B | $10.81B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Open Text Corporation (OTEX) trades at $23.62, down 4.45% in the past 24 hours, with a bullish technical signal despite bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.23 exceeding expectations. Valuation metrics appear attractive with a P/E of 9.29 and EV/EBITDA of 5.95, while profitability remains solid with a net income margin of 12.26% and ROE of 16.19%.
The outlook is positive given consistent earnings outperformance and a consensus price target of $29.33, implying 24% upside. Risks include high debt levels and competitive pressures in the software sector. Investor sentiment is mixed, with analysts showing cautious optimism amid recent institutional selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
